News from Freeline
Charlotte2022-04-13T15:50:45+02:00Freeline will be progressing to the second dose cohort in the MARVEL-1 study immediately with first patient dosing expected in mid-2022
Help us to train Face2Gene to diagnose Fabry patients earlier!
Charlotte2022-03-31T13:31:22+02:00Help us to train Face2Gene to diagnose Fabry patients earlier!
FIN Fabry Expert Meeting 2022 – May 7th
Charlotte2022-03-11T10:35:19+01:00Registration now open - Virtual FIN Fabry Expert Meeting 2022 on May 7th
News from Sangamo Therapeutics
Charlotte2022-02-08T16:29:44+01:00Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
Highlights of the WorldSymposium 2022
Charlotte2022-03-11T10:42:18+01:00Fabry Highlights from the Worldsymposium Webinar with Dr Hopkin Feb 28Th at 6pm CET
Fabry Expert Meeting 2022 – Virtual on May 7th
Charlotte2022-03-11T10:42:28+01:00Virtual Fabry Expert Meeting 2022 on May 7th
Addressing the Challenges of Persons Living with a Rare Disease
Charlotte2022-02-08T16:39:01+01:00Addressing the Challenges of Persons Living with a Rare Disease
Gene Therapy Approaches for Fabry Diseases
Charlotte2022-02-08T16:39:13+01:00We're are happy to share this great resource with you. This can support you in exploring different gene therapies approaches to treating Fabry disease! Have a look at the infographic to find out more!
News from Freeline
Charlotte2021-12-13T18:27:08+01:00Freeline announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs.